The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.
The pharmaceutical industry is fighting against a threat to companies' bottom lines: a global agreement which will harmonize corporation tax.
Blot clots are not more likely after second Astrazeneca jab, data published in The Lancet suggests.
Pharmaceutical company Biontech plans to create a vaccine for malaria based on the same mRNA technology as the firm's vaccine for covid-19, which the German company developed in collaboration with Pfizer.
The New York Times reports that vaccine studies involving children aged 5-11 will be made more comprehensive in the wake of a request from the FDA.
The US FDA has given biotech firm Saniona's drug candidate Tesomet priority status as an orphan drug for treating hypothalamic obesity. Earlier this year, Tesomet received the same priority status as a treatment for Prader-Willi syndrome.
Biotech company Allarity Therapeutics has divested a drug candidate to US Lantern Pharma, from which the Danish company in-licensed the drug in 2015. The deal may amount to USD 18m.
89 percent of the Swedish population above the age of 65 are fully vaccinated, meaning authorities in Sweden are phasing out the use of the AstraZeneca vaccine. In Stockholm, residents now have a choice of vaccines.
From now on, children aged between 12-17 may receive the Moderna vaccine against covid-119, according to the EU CHMP. The Danish Health Authority is taking note.
The acceleration in sales of Roche's Hemlibra, which competes with Novo Nordisk in an increasingly hot market, has continued. Sales for the first half year totaled more than USD 1.5bn.
A new phase III trial in the US will investigate whether extending the patient target group of Lundbeck's drug Vyepti to include younger patients is possible.
"We are now one of the world regions that has vaccinated the most people," says a spokesperson for the EU Commission.
Halfway through the accounting year, Biogen predicts a higher revenue than previously expected.
In less than a year, Danish biotech company Hemab, which builds on technology developed by Novo Nordisk and Genmab, has gone from seed investments to a large capital fund raising round – and now to clinical trials.
Johnson & Johnson's sales figures for Darzalex in the second quarter are so good that Genmab, which developed the drug, may increase its financial expectations for the year, says senior analyst Søren Løntoft Hansen.
Sales of Johnson & Johnson's drug Darzalex totaled USD 1.43bn in Q2, far surpassing analysts' expectations for the drug, which was originally developed by Genmab.
The launch of sclerosis treatment Kesimpta is continuing to go well for Novartis, which has exceeded its financial expectations for the second quarter of this year.
While Leo Pharma waits for a response to its approval application for eczema treatment Adtralza in the US, it is launching the treatment in the EU, where Head of Europe Monica Shaw can put the experience from launching psoriaris treatment Kyntheum to good use.
The European Medicines Agency has now started to assess Sanofi's coronavirus vaccine frequently, to ensure faster authorization of the jab if it lives up to the authority's requirements.
It is not just vaccine companies that see potential in using RNA technologies – Novo Nordisk also has agreements in place for the therapies.
The loan will be used to finance the clinical development of the biotech company's assets.
The pharmaceutical firm has worked with partner Epi Health to launch Wynzora on the US market, where it was authorized as a treatment for psoriasis last year.
Morten Søgaard, Head of Target Sciences at Pfizer, thinks the global community needs to prepare itself to be able to handle pandemics better in the future.
The intensive investments in the US and China that Pharmacosmos has made over the past few years have been expensive, but now, company leadership expects rewards.
The two pharmaceutical companies have been forced to announce that the FDA's processing of Olumiant as a treatment for atopic dermatitis has been delayed for a second time. This is due to questions surrounding the drug class.
Market Director, Alfanordic 
(Senior) Regulatory Science Specialist - IWA Consulting Senior Validation Analyst, Zealand Pharma 
Senior Clinical Supply Manager - Lundbeck 
Employee for regulatory department 
Regulatory Affairs Professional, CMC - ALK 
Senior Biostatistician - Vaccibody Principal Biostatistician - ALK 
We are expanding in CleanZone and we are looking for a technical product specialist and technical project manager 
Associate Director, PV QA - Y-mAbs Therapeutics 
Business developer within Medical Diagnostics Bio & Health Data Scientist - ALK-Abelló 2 Account Managers, Merck Life Science - Best Talent 
Analytical Coordinator - Symphogen Principal Scientist, In Vivo Pharmacology Associate Medical Director, Translational Medicine - Y-mAbs Therapeutics Senior QA Specialist - Vaccibody 
Manager/Associate Director Regulatory Affairs - Ascendis Pharma Drug Safety Advisor - ALK 
KLIFO is looking for a Senior QA Specialist for our Glostrup office Toxicologist - Lundbeck Medical Writer - Vaccibody Senior Downstream Scientist - Symphogen 
Sponsor Oversight Lead - Genmab Research Laboratory Technician, Immunology/Translational Research - ALK 
